Drugs / DT-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07610473 | Jun 2026 → May 2027 expected | major depressive disorder | Draig Therapeutics Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07300969 | Dec 2025 → Aug 2027 expected | major depressive disorder | Draig Therapeutics Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-28 | Draig Therapeutics Ltd | Results Draig Therapeutics Presents New Phase 1 Data Demonstrating Safety, Tolerability, Pulsatile PK and Target Engagement by DT-101, a Novel AMPA Receptor Potentiator, at ASCP Annual Meeting draigtherapeutics.com ↗ |
| 2025-10-02 | Draig Therapeutics Ltd | Regulatory Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of DT-101 for the Treatment of Major Depressive Disorder draigtherapeutics.com ↗
The decision follows US Food and Drug Administration (FDA) clearance of the IND application for the Phase 2 trial protocol. |
All press releases naming this drug 2 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DT-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300969 ↗ |